نتایج جستجو برای: transplantation hsct

تعداد نتایج: 143542  

Journal: :iranian journal of blood and cancer 0
soheila zareifar associate professor of pediatric hematology-oncology, department of pediatrics, shiraz university of medical sciences, shiraz, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (shiraz university of medical sciences) babak abdolkarimi assistant professor of pediatric hematology-oncology, lorestan university of medical sciences, khoramabad, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی لرستان (lorestan university of medical sciences) mohamadreza bordbar associate professor of pediatric hematology-oncology, department of pediatrics, shiraz university of medical sciences, shiraz, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (shiraz university of medical sciences) mehran karimi professor of pediatric hematology-oncology, department of pediatrics, shiraz university of medical sciences, shiraz, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (shiraz university of medical sciences) fazl saleh fellowship of pediatric hematology-oncology, department of pediatrics, shiraz university of medical sciences, shiraz, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (shiraz university of medical sciences) omidreza zekavat associate professor of pediatric hematology-oncology, department of pediatrics, shiraz university of medical sciences, shiraz, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (shiraz university of medical sciences)

background: burkitt lymphoma is a common subtype of non-hodgkin lymphoma in children. it has a rapid and aggressive clinical course with frequent involvement of bone marrow and central nervous system. systemic chemotherapy is the mainstay of the treatment for this malignancy in children. in this systematic review, we discuss autologous and allogeneic hematopoietic stem cell transplantation (hsc...

2012
Volkan Hazar Gülsün Karasu Vedat Uygun Mediha Akcan Alphan Küpesiz Akif Yeşilipek

OBJECTIVE The aim of this study was to document hematopoietic stem cell transplantation (HSCT) activity and trends at our treatment center. MATERIAL AND METHODS Data collected over a 10-year period were retrospectively analyzed, concentrating primarily on types of HSCT, transplant-related mortality (TRM), stem cell sources, indications for HSCT, and causes of death following HSCT. RESULTS I...

2018
Lanping Xu Hu Chen Jing Chen Mingzhe Han He Huang Yongrong Lai Daihong Liu Qifa Liu Ting Liu Ming Jiang Hanyun Ren Yongping Song Zimin Sun Jianmin Wang Depei Wu Daobin Zhou Ping Zou Kaiyan Liu Xiaojun Huang

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used to treat malignant hematological neoplasms and non-malignant hematological disorders. Approximately, 5000 allo-HSCT procedures are performed in China annually. Substantial progress has been made in haploidentical HSCT (HID-HSCT), pre-transplantation risk stratification, and donor selection in allo-HSCT, especially aft...

Journal: :international journal of hematology-oncology and stem cell research 0
mohammad vaezi hematologist- oncologist, hematology- oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran cyrous gharib hematologist- oncologist, gilan university of medical sciences, gilan, iran maryam souri 3hematology- oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran ardeshir ghavamzadeh professor of medicine, hematology-oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran

background: hematopoietic stem cell transplantation (hsct) is currently the only curative treatment for acute leukemia. as hsct improves the long-term survival, it is necessary to assess the late-onset complications affecting the quality of life following hsct. subjects and methods: the study included 122 patients (65 male, 57 female) with leukemia (72 aml and 50 all) who received transplants f...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004
Marcio Nucci Kieren A Marr Flavio Queiroz-Telles Carlos A Martins Plinio Trabasso Silvia Costa Julio C Voltarelli Arnaldo L Colombo Alexander Imhof Ricardo Pasquini Angelo Maiolino Cármino A Souza Elias Anaissie

To characterize the epidemiology and prognostic factors of invasive fusariosis in hematopoietic stem cell transplant (HSCT) recipients, the records of HSCT recipients from 9 hospitals (7 in Brazil and 2 in the United States) were retrospectively reviewed. Sixty-one cases were identified: 54 in allogeneic HSCT recipients and 7 in autologous HSCT recipients. The incidence of fusariosis among allo...

2017
Maya K. Sethi Felicitas Thol Michael Stadler Michael Heuser Arnold Ganser Christian Koenecke Oliver Pabst

After allogeneic hematopoietic stem cell transplantation (HSCT), recovery of humoral immunity is essential to protect from life-threatening infections. However, monitoring the humoral immune system after transplantation with standard techniques in the clinical routine is imprecise. Here, we performed sequencing of mononuclear bone marrow cells to characterize the VH1-repertoire of switched B ce...

Journal: :Cold Spring Harbor perspectives in medicine 2012
Guido Lucarelli Antonella Isgrò Pietro Sodani Javid Gaziev

The globally widespread single-gene disorders β-thalassemia and sickle cell anemia (SCA) can only be cured by allogeneic hematopoietic stem cell transplantation (HSCT). HSCT treatment of thalassemia has substantially improved over the last two decades, with advancements in preventive strategies, control of transplant-related complications, and preparative regimens. A risk class-based transplant...

Journal: :The Egyptian Journal of Hospital Medicine 2021

Background: Graft-versus-host disease (GVHD) is the major complication after allogeneic hematopoietic stem cell (HSCT) transplantation. GVHD prophylaxis based on use of calcineurin inhibitors. With haploidentical HSCT, cyclophosphamide increased implantation (PT-Cy). Objectives: Compare clinical outcome HSCT PT-Cy versus methotrexate (MTX) regimens Patients and methods: we included 137 patien...

2010
L. ROZIAKOVA

Hematopoietic stem cell transplantation (HSCT) offers patients with malignant and nonmalignant diseases the oportunity to pursue life-prolonging therapy. The number of survivors after successful HSCT is continually increasing. However, HSCT can induce tissue and organ damage that occurs not only “on treatment” , but long after completing therapy. Secondary malignancies belong to serious late co...

Journal: :Blood 2014
Yi Luo Haowen Xiao Xiaoyu Lai Jimin Shi Yamin Tan Jingsong He Wanzhuo Xie Weiyan Zheng Yuanyuan Zhu Xiujin Ye Xiaohong Yu Zhen Cai Maofang Lin He Huang

We developed an approach of T-cell-replete haploidentical hematopoietic stem cell transplantation (HSCT) with low-dose anti-T-lymphocyte globulin and prospectively compared outcomes of all contemporaneous T-cell-replete HSCT performed at our center using matched sibling donors (MSDs), unrelated donors (URDs), and haploidentical related donors (HRDs). From 2008 to 2013, 90 patients underwent MSD...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید